Evaluation of uroprotective efficacy of amifostine against cyclophosphamide induced hemorrhagic cystitis.
The role of amifostine in the prevention of cyclophosphamide-induced hemorrhagic cystitis (HC) was evaluated in the rat model. Urinary bladders from control rats that received no drugs (group I) were compared with those from rats receiving cyclophosphamide alone at a dose of 150 mg/kg (group II), and two other groups receiving amifostine at 100 mg/kg (group III) and 200 mg/kg (group IV), 15 min prior to cyclophosphamide. Bladders were assessed macroscopically and histologically at 24 h and after 7 days. All the animals that received cyclophosphamide alone developed severe HC. On the basis of the scores of macroscopic and histologic changes, animals that received amifostine showed excellent uroprotection. Only 2/6 rats in group III and 1/6 rats in group IV developed mild HC at 24 h. None of the rats in either of these groups showed any evidence of HC at 7 days. It is concluded that amifostine protects the urothelium against cyclophosphamide-induced HC.
Srivastava
A
A
Department of Hematology, Christian Medical College Hospital, Vellore, India.
Nair
S C
SC
Srivastava
V M
VM
Balamurugan
A N
AN
Jeyaseelan
L
L
Chandy
M
M
Gunasekaran
S
S
D004999:Amifostine / Q000494:pharmacology*; D000818:Animals; D002273:Carcinogens / Q000633:toxicity; D003520:Cyclophosphamide / Q000633:toxicity; D003556:Cystitis / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D006470:Hemorrhage / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control; D011837:Radiation-Protective Agents / Q000494:pharmacology*; D051381:Rats; D001743:Urinary Bladder / Q000187:drug effects / Q000503:physiopathology
D002273:Carcinogens; D011837:Radiation-Protective Agents; D003520:Cyclophosphamide; D004999:Amifostine